Adjuvant and Neoadjuvant Therapy for NSCLC: Who to Treat and With What Agent

Peer-Spectives

English - May 05, 2022 01:46 - 12 minutes - 22.5 MB
Science Education obr oncology cancer healthcare medical obroncology peerspectives robertfiglin Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: The Complex Decisions in CLL Treatment Today: Clarifying the Choices

Next Episode: Most Patients with BRAF-mutant Metastatic Melanoma Benefit from First-line Immunotherapy

Listen in as Roy Herbst, MD, PhD, shares with Robert Figlin, MD, how he approaches treatment for patients with early-stage non-small cell lung cancer after the ADAURA and CHECKMATE-816 trials. They discuss different factors that influence use of adjuvant and neoadjuvant treatments, including stage, EGFR mutation status, and PD-L1 status.